

CORTAZ FOAM

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.
Abbreviated Prescribing information for CORTAZ FOAM (Clobetasol Propionate Topical
Foam 0.05% w/w)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

Mechanism of action: Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A₂ inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid.

Arachidonic acid is released from membrane phospholipids by phospholipase A₂.

DOSAGE AND ADMINISTRATION: For external use only. Shake well before every use.
Not recommended for children below 12 years.

CONTRAINDICATION: Rosacea, Acne vulgaris, Perioral dermatitis, Perianal and genital pruritus, Primary cutaneous viral infections (e.g. herpes simplex, chickenpox), Hypersensitivity to the active substance or to any of the excipients. The use of Clobetasol skin preparations is not indicated in the treatment of primary infected skin lesions caused by infection with fungi (e.g. candidiasis, tinea) or bacteria (E.g. impetigo). Dermatoses in children under 12 years of age, including dermatitis and napkin eruptions.

WARNINGS & PRECAUTIONS: : Contents under pressure. Do not puncture or incinerate container, or expose to heat. Flammable, avoid proximity to flame or smoking during and immediately after use, Visual disturbances.

ADVERSE REACTIONS: Immune system disorders- Hypersensitivity, Endocrine disorders- Features of Cushing's syndrome, Adrenal insufficiency on abrupt withdrawal, Eye disorders- Vision blurred, Vascular disorders- Dilatation of the superficial blood vessels, Skin and subcutaneous tissue disorders- Local skin burning, local atrophy, striae, thinning, pigmentation changes, hypertrichosis, exacerbation of underlying symptoms, pustular psoriasis.

Marketed BY:



TORRENT PHARMACEUTICALS LTD.

IN/CORTAZ FOAM/JUL-21/02/ABPI

(Additional information is available on request)